<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>70</patient-age><report-id>PHHO2012CN017597</report-id><gender>female</gender><reactions><reaction>Death/Progression of study indication</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>AFINITOR </drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Metastatic renal cell carcinoma</indication></indications><outcomes><outcome>Death</outcome></outcomes><country>China</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053229_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134654</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHO2012CN017597</safetyreportid>
		<primarysourcecountry>CN</primarysourcecountry>
		<occurcountry>CN</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-07</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-10</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2012CN017597</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Wang</reportergivename>
			<reporterfamilyname>Jin Wan</reporterfamilyname>
			<reporterorganization>Cancer Institute &amp; Hospital, Chinese Academy of Medical Scie</reporterorganization>
			<reporterstreet>No. 17 Pan-Jia-Yuan Rd, Chao Yang District</reporterstreet>
			<reportercity>Beijing</reportercity>
			<reporterpostcode>100021</reporterpostcode>
			<reportercountry>CN</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CRAD001L2404</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Yang</reportergivename>
			<reporterfamilyname>Lin</reporterfamilyname>
			<reporterorganization>Cancer Institute &amp; Hospital, Chinese Academy of Medical Scie</reporterorganization>
			<reporterstreet>No. 17 Pan-Jia-Yuan Rd, Chao Yang District</reporterstreet>
			<reportercity>Beijing</reportercity>
			<reporterpostcode>100021</reporterpostcode>
			<reportercountry>CN</reportercountry>
			<qualification code="1">Physician</qualification>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>MHZ</patientinitial>
			<patientinvestigationnumb>20006</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19420706</patientbirthdate>
			<patientweight>58</patientweight>
			<patientheight>146</patientheight>
			<patientsex code="2">Female</patientsex>
			<patientdeath>
				<patientdeathdateformat>102</patientdeathdateformat>
				<patientdeathdate>20121126</patientdeathdate>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Disease progression</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Death/Progression of study indication</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Disease progression</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Disease progression</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121126</reactionstartdate>
				<reactionfirsttime>77</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>19</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="5">fatal</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AFINITOR </medicinalproduct>
				<obtaindrugcountry>CN</obtaindrugcountry>
				<drugauthorizationnumb>22-334</drugauthorizationnumb>
				<drugauthorizationcountry>CN</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>590</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>10 mg, QD</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Metastatic renal cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-09-11</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-08</drugenddate>
				<drugtreatmentduration>59</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Disease progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2012CN017597, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>report received on 07 Dec 2012, from clinical study CRAD001L2404. This 70-year old female subject [subject number 20006, centre number 3701] was enrolled in an open label, multicentre phase II study to examine the efficacy and safety of <Semaphore x="558929" class="Medicine" value="everolimus" score="0.49" ID="232653">everolimus </Semaphore>as <Semaphore x="2502709" class="Procedure" value="Second Line Treatment" score="1.00" ID="C54350">second line therapy </Semaphore>in the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of patients with <Semaphore x="2221866" class="Disease or Finding" value="Metastatic Carcinoma" score="1.00" ID="C3482">metastatic <Semaphore x="2458655" class="Disease or Finding" value="Renal Carcinoma" score="1.00" ID="C9384">renal <Semaphore x="2153863" class="Disease or Finding" value="Malignant Epithelial Cells with Abundant Clear Cytoplasm Containing Glycogen Present" score="1.00" ID="C54715">cell carcinoma </Semaphore></Semaphore></Semaphore>(RECORD 4).The subject received the <Semaphore x="2394286" class="Procedure" value="Pharmacotherapy" score="1.00" ID="C15986">treatment with the study medication </Semaphore>RAD at a dose of 10 mg on 11 Sep 2012 and received the last dose on 08 Nov 2012, prior to the event. On 09 Nov 2012, the subject experienced progression of study indication. On 26 Nov 2012, the subject died, due to progression of study indication. It was unknown that <Semaphore x="1558453" class="Disease or Finding" value="Autopsy TNM Finding" score="1.00" ID="C48882">autopsy </Semaphore>was performed or not. Action taken with the study medication was unknown. The investigator assessed the event as serious (fatal). The investigator reported that the event <Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">death </Semaphore>was due to <Semaphore x="2872356" class="MedDRA LLT" value="Concomitant disease progression" score="1.00" ID="10048659">progression of concomitant disease </Semaphore>(study indication).The investigator did not suspect a relationship between the event and the study medication.Follow up report received on 10 Dec 2012: Updated causality.</narrativeincludeclinical>
				<sendercomment>MR: Concur with the investigator that event progression of study indication was not related to study medication.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>